What's happened
Recent studies reveal that semaglutide, used in drugs like Wegovy and Ozempic, is associated with increased risk of ischaemic optic neuropathy, especially at higher doses. Men are three times more likely to experience this. Regulatory bodies are monitoring reports of adverse effects, including rare cases of vision loss.
What's behind the headline?
The emerging link between semaglutide and eye stroke signals a dose-dependent safety concern that warrants urgent attention. The data shows Wegovy, which employs higher doses, has a nearly fivefold increased risk of ischaemic optic neuropathy (ION) compared to Ozempic. The fact that men are three times more likely to experience this suggests sex-specific vulnerabilities. The absence of ION reports with Rybelsus, an oral form with slower absorption, indicates that administration method and dosage are critical factors. Regulatory agencies like the MHRA and FDA are now scrutinizing these reports, emphasizing the importance of cautious prescribing. While the benefits of semaglutide for weight loss and diabetes management are significant, these findings underscore the need for careful patient monitoring, especially for rapid weight loss and high-dose treatments. The potential for permanent vision loss makes this a serious safety issue that should influence future guidelines and patient education. Overall, this story highlights the importance of post-market surveillance in identifying rare but severe adverse effects that may not be evident in clinical trials, and it signals a need for updated regulatory guidance to mitigate risks.
What the papers say
The Independent reports that the FDA's adverse event database shows Wegovy has a nearly five times higher association with eye stroke compared to Ozempic, with men being three times more affected. The study emphasizes dose and formulation dependency, with Wegovy's higher doses being a key factor. The article also notes that Rybelsus, an oral form, has not been linked to ION, likely due to slower absorption. The MHRA in the UK has received reports of deaths suspected to be linked to GLP-1 medications, including Mounjaro and unspecified semaglutide, with ongoing safety monitoring. The Independent highlights that regulatory bodies are actively reviewing these reports, stressing that benefits outweigh risks but urging caution. Conversely, The New York Post emphasizes the increased risk of ION with Wegovy and Ozempic, noting that the higher doses and injection methods may contribute to the problem. Both sources agree on the importance of cautious use and further investigation, but the Post underscores the rarity of these events in the general population and the need for individual risk assessment. The Guardian's coverage, not included here, would likely focus on the broader implications for drug safety and regulatory oversight, but the provided articles collectively stress the importance of ongoing vigilance and patient safety in the context of these widely used medications.
How we got here
Semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is a GLP-1 receptor agonist prescribed for obesity and diabetes. Its use has increased globally, with reports of adverse effects emerging from post-market surveillance. Recent research analyzed FDA adverse event data from 2017 to 2024, highlighting potential safety concerns related to eye health, particularly at higher doses used in weight management drugs.
Go deeper
More on these topics
-
Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management.
-
The British Journal of Ophthalmology is a peer-reviewed medical journal covering all aspects of ophthalmology. The journal was established in 1917 by the amalgamation of the Royal London Ophthalmic Hospital Reports with the Ophthalmoscope and the Ophthalm
-
The Food and Drug Administration is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
-
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares.